Literature DB >> 3758188

Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy.

W Löscher, S J Czuczwar.   

Abstract

Dopamine agonists with different selectivity for dopamine D-1 and D-2 receptors in the brain were tested for their effects: on thresholds for maximal electroshock seizures in mice and rats and for pentylenetetrazol-induced clonic seizures in mice; on seizures induced by air blast stimulation in gerbils, and on seizures induced by amygdala-kindling in rats. The mixed D-1/D-2 agonist apomorphine exerted anticonvulsant effects in all models except kindling. In gerbils and mice, the anticonvulsant action of apomorphine could be antagonized by the D-2 selective dopamine antagonist sulpiride. When injected alone, sulpiride exerted no significant effect on seizure activity. The preferential D-2 receptor agonists lisuride and (+)-PHNO [+)-4-propyl-9-hydroxynaphthoxazine) differed in their profile of action. Both compounds displayed anticonvulsant efficacy in gerbils, while only lisuride proved capable of reducing kindled seizure severity. (+)-PHNO increased the threshold for electroconvulsions in mice while lisuride was ineffective in this respect or even decreased the threshold. The reverse was obtained in regard to electroshock seizures in rats. The threshold for seizures induced by pentylenetetrazol in mice was increased significantly by lisuride but not by (+)-PHNO. The selective dopamine D-1 receptor agonist SKF 38393-A exerted no anticonvulsant effect in any seizure test except a moderate increase of the electroconvulsive threshold in mice. In contrast, the dopamine precursor L-DOPA (injected after pretreatment with carbidopa) proved capable of reducing seizure activity in all models. In mice, the increase in the threshold for maximal electroshock seizures induced by L-DOPA was significantly reduced by sulpiride, which also attenuated the anticonvulsant effect of L-DOPA in gerbils. Collectively, the data indicate that dopamine D-2 receptors mediate the anticonvulsant effect of dopamine agonist and, at least in part, of L-DOPA whereas D-1 receptors seem not to be involved.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758188     DOI: 10.1016/0014-2999(86)90557-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Biochemical events in spontaneous seizures in the Mongolian gerbil.

Authors:  R Wolf-Dieter; G Heuschneider; G Sperk; P Riederer
Journal:  Metab Brain Dis       Date:  1989-03       Impact factor: 3.584

2.  Effect of amygdaloid kindling on rat striatal dopamine D1- and D2-receptors.

Authors:  R Allin; M Mintz; V Russell; A Engelbrecht; M Lamm; W Daniels; G van der Spuy; A Jaffer; L Kellaway; J Taljaard
Journal:  Neurochem Res       Date:  1994-07       Impact factor: 3.996

3.  High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

Review 4.  The role of the basal ganglia in the control of seizure.

Authors:  J Vuong; Annaelle Devergnas
Journal:  J Neural Transm (Vienna)       Date:  2017-08-01       Impact factor: 3.575

5.  Potential Pleiotropic Genes and Shared Biological Pathways in Epilepsy and Depression Based on GWAS Summary Statistics.

Authors:  Han Lin; Wan-Hui Lin; Feng Lin; Chang-Yun Liu; Chun-Hui Che; Hua-Pin Huang
Journal:  Comput Intell Neurosci       Date:  2022-04-12

6.  Trimetazidine, an Anti-Ischemic Drug, Reduces the Antielectroshock Effects of Certain First-Generation Antiepileptic Drugs.

Authors:  Kinga Borowicz-Reutt; Monika Banach
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

7.  Drug repurposing for Dravet syndrome in scn1Lab-/- mutant zebrafish.

Authors:  Jo Sourbron; Michèle Partoens; Chloë Scheldeman; Yifan Zhang; Lieven Lagae; Peter de Witte
Journal:  Epilepsia       Date:  2019-01-20       Impact factor: 5.864

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.